Open access peer-reviewed chapter

From Rat Poison to Medicine: Medical Applications of Coumarin Derivatives

Written By

Robbert Bipat

Submitted: July 11th, 2019 Reviewed: September 17th, 2019 Published: October 17th, 2019

DOI: 10.5772/intechopen.89765

From the Edited Volume

Phytochemicals in Human Health

Edited by Venketeshwer Rao, Dennis Mans and Leticia Rao

Chapter metrics overview

888 Chapter Downloads

View Full Metrics

Abstract

Historical reports mention the application of medicinal plants containing coumarins against various ailments. Current research suggests that at least some of the actions described may be attributable to the action of these coumarins. Warfarin and its derivatives are coumarins used today in medical practice. Their mechanism of action lies in the competitive antagonism of vitamin K, through which they inhibit coagulation in the body by preventing the production of prothrombin. Due to this action, these coumarins are a major group of drugs with anticoagulant activity. Anticoagulants reduce the risks of undesirable blood clots leading to myocardial infarction, pulmonary embolism, and ischemic stroke among others. The anticoagulant activity can also lead to undesired bleeding. Extreme caution is warranted when given to menstruating women, patients suffering from disorders prone to bleeding like gastric ulcer and rheumatoid arthritis, and to persons with a high likelihood of blunt and sharp trauma. In addition, there is a significant augmentation of the anticoagulant activity when used in combination with non-steroidal anti-inflammatory agents and agents interfering with the metabolism of the coumarins. Recent findings propose additional uses like anti-tumor and antibiotic actions for coumarins. The clinical application of these actions has yet to be demonstrated.

Keywords

  • warfarin
  • coumarin
  • anticoagulant
  • prothrombin
  • coagulation cascade
  • adverse reaction
  • rodenticide
  • embryopathy
  • vitamin K

1. Introduction

Coumarins are members of the benzopyrone class of organic compounds that are found in many plants [1] and possess a variety of pharmacological properties such as antimicrobial, anti-inflammatory, antidiabetic, and antioxidant activity, as well as a significant influence on physiological processes like enzyme inhibitory activity [2]. Despite the wide availability of coumarins and their lead compounds and metabolites in natural products [3], their application up till now has been mostly limited to the anticoagulant activity of warfarin derived from dicoumarol and its analogues [4]. The mechanism of action of these anticoagulants lies in the competitive antagonism of vitamin K, through which they inhibit coagulation of blood in the body by preventing the production of prothrombin and several other coagulation factors [5]. Due to this action, these coumarins are a major group of oral drugs with anticoagulant activity. Anticoagulants reduce the risks of undesirable blood clots leading to myocardial infarction, pulmonary embolism, and ischemic stroke among others. This chapter gives an overview of medical applications of coumarins, in particular the history and evolution of warfarin and related compounds as important anticoagulant agents.

Advertisement

2. History

The medical application of plants containing coumarins probably started long before the isolation of this chemical compound from the Tonka bean in 1820 by Nicholas Jean Baptiste Gaston Guibourt [6]. Ancient Romans produced a cough syrup from the marshmallow (Althea officinalis) [7], which contains the coumarin scopoletin [8]. This coumarin demonstrated inhibition of leucocyte migration in mice [9], a process that can be linked to the alleged antitussive effect. Cough is a result of the reaction of the airways to leukotrienes and other factors secreted by leucocytes [10, 11, 12]. Inhibition of the migration of these to the affected region consequently reduces the availability of these paracrine factors. In addition, at least one of the herbs mentioned by the famous Roman General Pliny in his pharmacopeia [13] contain coumarins with proven action. For example, the extracts of the common rue or herb-of-grace Ruta graveolens contain xanthotoxin [14], a coumarin that reduces the mobility of human spermatozoa possibly through inhibition of membranaeous potassium channels [15].

The application of coumarin and its derivatives in current western medicine dates to the fifties of the past century with the clinical recognition of coumarins as anticoagulant agents. This event was the result of observations of poisoning of animals with coumarin derivatives that led to massive internal organ bleeding [16]. Soon it became clear that the substance that was responsible for the deadly internal bleeding of cattle was dicoumarol [17]. Shortly after this, the proposal was made to develop a coumarin derivative with rodent killing ability and gradually warfarin found its application as a potent rodenticide [18]. When it became clear that this substance also led to bleeding disorders after poisoning in human beings [19], its application as a therapeutic anticoagulant found its way in medicine [20, 21]. Seven decades later, warfarin is still in use as an anticoagulant [22]. In the meantime, several other coumarins with anticoagulant properties like acenocoumarol, phenprocoumon, and fluindione have been developed, and they are used in a variety of clinical settings [23, 24, 25].

Advertisement

3. Physiology of hemostasis

Hemostasis in mammals and humans is the result of three sequential processes. The first of these is the acute vasoconstriction within seconds after damaged arteries and veins, by local activity of the potent vasoconstrictor thromboxane among others [26]. The second step is the formation of a blood clot through the entrapment of platelets by fibrin within hours and finally followed by the organization of the fibrin mesh into an adhesive structure on the vessel wall [27]. In one of the last steps of the coagulation, prothrombin converts to thrombin, an enzyme that converts the plasma protein fibrinogen to fibrin monomers and activates factor XIII of the coagulation cascade. Activated factor XIII synthesizes fibrin from these monomers. The acquired fibrin molecules then trap the platelets and eventually form the blood clot [27, 28]. The coagulation process has both an intrinsic and an extrinsic pathway. The difference is that the intrinsic pathway only requires ionized calcium to be activated while the extrinsic pathway requires both calcium and tissue factor that is released with trauma [28]. Figure 1 gives an overview of the coagulation process along with the interference sites of warfarin.

Figure 1.

Overview of the coagulation process along with the interference sites of warfarin.

Advertisement

4. Pharmacology

4.1 Pharmacokinetics

Warfarin is highly lipid soluble [29, 30, 31]. Between 70 and 100% of the oral intake is rapidly absorbed by the intestines with a maximum plasma concentration within 2 h after oral intake [30]. The half-life of the drug is generally more than 20 h, with a large individual variety [32]. Due to the overt lipid solubility, the major part of the drug is protein bound with less than 3% being biologically available [29]. Consequently, the agent has a slow onset of action and a long duration of activity [33]. In fact, the optimal effect is delayed for a few days, until all remaining activated factors II, VII, IX, and X are depleted from the liver and the circulation [33]. Warfarin accumulates in the liver where it exerts its effect and is inactivated through oxidative metabolism by cytochromes P450 to several isomers of water-soluble hydroxywarfarin with negligible anticoagulant activity [34, 35]. These metabolites are almost completely cleared by the kidneys [36]. The hepatic accumulation and relative easy absorption in the intestines result in an enterohepatic circulation of the drug [37]. Enterohepatic circulation is a process in which substances are secreted by the liver with bile to the intestines and subsequently absorbed again by the latter [28]. This results in recycling of the product with very little elimination.

4.2 Mechanism of action

Warfarin inhibits the enzyme vitamin K epoxide reductase that recycles oxidized vitamin K [38]. Vitamin K activates the coagulating factors prothrombin (factor II) and the structurally related serine proteases known as factors VII, IX, and X in the liver cells [27]. Decreasing the biological availability of vitamin K inhibits the synthesis of these essential factors and eventually leads to inhibition of the coagulation process. This means that this compound affects both the intrinsic as well as the extrinsic cascade of coagulation since prothrombin plays a central role in both of these pathways [28] and renders it a highly effective anticoagulant drug.

Advertisement

5. Indications and contraindications

Hemostasis is an essential process to prevent significant external as well as internal blood loss after injury. However, under certain circumstances, it is not desirable to activate or continue this homeostatic process like in disorders with spontaneous thrombosis such as deep venous thrombosis in the legs often resulting in pulmonary embolism [39]. In addition, there are conditions that are prone to a reasonable chance of forming a blood clot during stasis of the blood circulation like in atrial fibrillation and in the limbs of patients with prolonged immobility after surgery [39]. Moreover, conditions like myocardial infarction or ischemic stroke form a preventable group of disorders with inhibition of the thrombotic process [5]. Based on its anticoagulant properties, warfarin is thus an ideal compound for the treatment and prevention of these thromboembolic conditions [5].

Based on the pharmacokinetic properties and the challenges they present, dosing of warfarin is not simple, and a careful approach is necessary. On one hand, a low plasma concentration will not achieve the effect of sufficient anticoagulation and, on the other side of the spectrum, there is the constant chance of overdosing with potential lethal internal or external bleeding. Another problem is the great variety of absorption, body distribution, and metabolism of the agent with individual patients based on the pharmacokinetic properties of warfarin [30]. Frequent monitoring of therapeutic efficiency with adequate laboratory tools like prothrombin time (PT) or international normalized ratio (INR) is absolutely necessary [40, 41] and a fixed or constant dose is close to impossible. Nevertheless, warfarin is highly effective in anticoagulation regiments when carefully dosing and assessing the potential bleeding sites as well as other potential side effects. Warfarin is initially dosed at 5–10 mg daily [42]. Subsequent doses depend on the international normalized ratio, with a therapeutic value between 2 and 4. Concomitant administration of heparins like fraxiparine is necessary when fast anticoagulant activity is desirable [43].

Warfarin is not an ideal agent in conditions when immediate treatment of thromboembolism is imminent due to the long time of onset. In cases of pulmonary embolism and acute ischemic stroke, it is desirable to start with both the oral anticoagulant and fast-acting agent like heparins [44]. The long duration of action harbors another challenge. When acute termination of anticoagulation is necessary with unwanted bleeding like in menstruating women and after blunt and sharp trauma leading to hemorrhage, it could take days before the process of coagulation completely restores after quitting oral administration [27, 30] due to the depletion of coagulant factors in liver and blood. In these cases, intravenous administration of prothrombin complex, fresh frozen plasma with coagulation factors, and high doses of vitamin K may be helpful [45].

Warfarin readily passes the placenta and may result in spontaneous abortion due to retroplacental bleeding [46], as well as prematurity [47], fetal deformity [48], stillbirth [48], and fetal cranial bleeding [49]. Administration during the first trimester of pregnancy has a high risk of embryopathy [50]. This is accompanied by deformities of bone and cartilage [51], blindness, mental retardation, and other neurologic abnormalities [52]. The occurrence of these complications and defects seem to be dose dependent [47, 53] and are most probably the result of the interference with vitamin K-dependent coagulation [38] and bone formation [54]. The effects of the central nervous system and the blindness are probably the result of microhemorrhages in the developing brain as a result of the anticoagulant activity [55]. Clotting factors are easily depleted in the fetus due to the immature liver and small circulating volume [46]. Warfarin does not enter breastmilk and is thus completely safe during lactation [56].

In conclusion, warfarin must be administered with great caution to women in their child-bearing age [57]. Therapy with this agent must be ceased immediately when it becomes clear that the patient is pregnant. Low-molecular weight heparins are a good alternative, since they do not cross the placenta and have been proven to be safe for mother, embryo, and fetus [58].

Advertisement

6. Drawbacks and side-effects

To say that anticoagulant coumarins have only a few side effects is an absolute understatement. Warfarin is one of the leading drugs with adverse effects requiring hospital admission [59]. Most of all, there is the constant chance of severe bleeding [60]. This can include internal hemorrhagic conditions in the head, gastrointestinal tract, female genitalia, the bladder and urethra or skeletal joints and muscles [40, 61]. They generally present as severe headache, stomach pain, and black or bloody stool, heavier than normal menstrual bleeding, discoloration of urine, and pain and swelling of the joints or muscles. Prolonged bleeding from external sharp or blunt wounds is always present [61]. All these conditions are the result of inability of the affected tissues to initiate and continue the process of hemostasis after damage to the epithelial barrier [62].

Patients suffering from hypertension, disorders of the liver, bleeding lesions, and the elderly and patients using drugs and substances that affect coagulation are at higher risk to suffer from bleeding when using warfarin [63]. Hypertension poses mechanical defects in the blood vessels, especially the arteries. Disorders of the liver reduce the ability of the body to eliminate the warfarin and thus make it more biologically available. In bleeding lesions, warfarin inhibits hemostasis. Among substances that can lead to bleeding when used with warfarin are steroidal and non-steroidal anti-inflammatory drugs, antibiotics, and alcohol. These potentiate the activity, interfere with the protein binding, and reduce the metabolism of warfarin, respectively [63]. Other side effects include injury to the kidneys with potential nephritis [64, 65, 66], inflammation of the skin [67] and blood vessels [66], and potentiation of rhabdomyolysis by simvastatin [64].

Due to resistance of rodents against warfarin, superwarfarins have been created [68]. These have a much longer time of activity and hence need only to be consumed once by the rodents, contrary to warfarin. The result however is that their effect persists much longer when deliberately or accidently consumed by humans [69] and treatment of this intoxication is a more challenging enterprise.

Advertisement

7. Interaction with drugs and foods

The efficacy of the anticoagulant treatment with warfarin highly depends on its bioavailability, since inhibition of the target (epoxy reductase) enzyme depends on direct binding of the drug to this protein [38]. In addition, vitamin K from external sources does not rely on recycling through this enzyme [38]. Hence, the absorption, transport, delivery, and elimination of warfarin as well as the external availability of vitamin K are potential sites of interaction with other drugs and with food and dietary supplements.

Drugs and food that influence the enterohepatic circulation can all affect the absorption of warfarin. Examples of these are the drug cholestyramine [37] and the avocado fruit [70], which prevent the reabsorption of warfarin in the intestines Concomitant administration of other protein-bound drugs may lead to greater amounts of circulating warfarin and increased risks of bleeding. Valproate sodium increases the bioavailability of warfarin through dislocation of its protein-binding sites [71]. Interference with the metabolism of warfarin is a potential of most drugs that are eliminated by hepatic metabolism. Among these are aspirin [72], nonsteroidal anti-inflammatory drugs [72], serotonin reuptake inhibitors [49], antiplatelet agents and some antibiotics [72]. It can go both ways with the metabolism. Induction of the cytochromes will increase the elimination, while occupation of the binding sites by the drugs will increase the availability of warfarin.

Since warfarin acts through elimination of available bioactive vitamin K, variations of the net intake of this vitamin will certainly interfere with the drug action. A high intake of the vitamin will keep the coagulant factors at a higher level and thus inhibit the anticoagulant activity. Likewise, a lower intake will potentiate the effect of warfarin. The vitamin occurs in food in the form of phylloquinone and menaquinone. Phylloquinone is the form mostly found in plants and is also the most abundant form in food [73]. Menaquinones are mainly the product of bacterial production or conversion [74]. Consequently, simple multivitamin and other supplements, food with high vitamin K content [74] as well as antibiotics are sources of fluctuation in vitamin K intake since intestinal bacteria significantly contribute to the production of menaquinones [75].

Recently, another source of interference came into focus. In addition to the previous mentioned parameters, genetic variation in the expression of cytochrome P450 seems to play a role in the metabolism of warfarin [76], thus influencing the availability of the drug [77]. All these considerations make it clear that close monitoring of the individual coagulation ability is necessary for a successful therapy with this agent.

The abovementioned interactions are just a few of the many that are possible. Table 1 gives examples of a variety of interactions with drugs, food, natural products, and supplements. This is only to underscore the cautious approach patients should practice when taking warfarin.

AgentCategoryPossible mechanismEffectReference
Allopathic medicationsAmiodaroneAntiarrhythmicInhibition of hepatic metabolism[78]
CiprofloxacinAntibioticReduction of vitamin K synthesis by intestinal bacteriaIncreased bleeding[79]
ParoxetineAntidepressantInhibition of hepatic metabolismPotentiation[80]
CitalopramAntidepressantInhibition of hepatic metabolismPotentiation[80]
ClopidogrelAntiplatelet medicationInhibition of coagulation cascadePotentiation[81]
DipyridamoleAntiplatelet medicationInhibition of coagulation cascadePotentiation[81]
DiclofenacNSAIDInhibition of coagulation cascadePotentiation[82]
NaproxenNSAIDInhibition of coagulation cascadePotentiation[82]
AcetaminophenAnalgesicInterference with hepatic metabolismIncreased bleeding[83]
Food supplementsFish oilLipid profile improvementInhibition of coagulation cascade?Potentiation[84]
Pomegranate juiceAntioxidantInterference with hepatic metabolismPotentiation[85]
GlucosamineCartilage improvementUnknownPotentiation[86]
Traditional medicationsChamomileMedicinal herbal teaUnknownIncreased bleeding[87]
GinsengImproving cognitive functionsUnknownInhibition[88]
St John’s wortAgainst depressionInduction of metabolismInhibition[89]

Table 1.

Brief overview of possible interactions with warfarin.

Advertisement

8. Future prospects and conclusion

Today, coumarins find their application predominantly as anticoagulants in medicine. The narrow therapeutic index of warfarin and related compounds sometimes limit their applicability and consequently there is a constant search for more safe agents in this drug class [90]. Unfortunately, the development of these will probably limit the use of these oral anticoagulants.

Aside from these developments, coumarins with several applications in medical practice are progressively being introduced. Investigators found that coumarin-3-carboxylic acid could be utilized as a dosimeter for radiotherapy. This substance converts to the highly fluorescent 7-hydroxy-coumarin-3-carboxylic acid, with a near perfect linear correlation upon irradiation [91].

The coumarin 2-hydroxycinnamic acid demonstrated inhibitive properties on the enzyme carbonic anhydrase [92]. Inhibition of this enzyme leads to diuresis [93] and decreases intraocular pressure in glaucoma patients [93] with clear therapeutic potential and clinical perspective.

Furano(pyrano)coumarins found in the roots of the Korean angelica (Angelica gigas) showed antibacterial activity in hay bacillus (Bacillus subtilis) cultures [94]. The coumarine derivative cloricromene reduced the inflammatory parameters in rats subjected to collagen-induced arthritis [95]. In addition, several studies found that coumarins may be useful as anti-tumor agents [4, 96].

Probably since ancient times, coumarins found their application in medicine. Currently, however, coumarins with predominantly anticoagulant properties are applied in daily medical practice. These have been developed from the initial discovery of a cattle killing weed more than six decades ago. Initially applied as a rodenticide, soon a therapeutic usable oral anticoagulant was developed, and slowly other agents entered the market. They have a small therapeutic index, rendering them toxic in a number of circumstances. The search for more safe agents with anticoagulant effects is ongoing and this may result in a decline of the use of coumarins in this field. Nevertheless, coumarins gradually find their way in other fields of medicine. Nevertheless, all these developments promise a bright future for coumarins in medical applications.

Advertisement

Conflict of interest

The author declares no conflict of interest.

Advertisement

Thanks

My gratitude goes out to my colleague Prof. Dr Dennis Mans, who encouraged me to write this chapter. I also want to thank the Anton de Kom University of Suriname for allowing me to do this on top of my regular job.

I want to thank my lovely wife and children who understand why I spend so much time in front of my PC. You are all such a supporting force for me.

References

  1. 1. Sarker SD, Nahar L. Progress in the chemistry of naturally occurring coumarins. In: Progress in the Chemistry of Organic Natural Products. New York: Springer; 2017. pp. 241-304
  2. 2. Wu L, Wang X, Xu W, Farzaneh F, Xu R. The structure and pharmacological functions of coumarins and their derivatives. Current Medicinal Chemistry. 2009;16:4236-4260
  3. 3. Venugopala KN, Rashmi V, Odhav B. Review on natural coumarin lead compounds for their pharmacological activity. BioMed Research International. 2013;2013:1-14
  4. 4. Rohini K, Srikumar PS. Therapeutic role of coumarins and coumarin-related compounds. Journal of Thermodynamics & Catalysis. 2014;05:1-3
  5. 5. Tadros R, Shakib S. Warfarin—Indications, risks and drug interactions. Australian Family Physician. 2010;39:476-479
  6. 6. Guibourt N-J-B-G. Histoire naturelle des drogues simples, ou Cours d’histoire naturelle professé à l’École de pharmacie de Paris. Libraire de L’Académie Nationale de Médicine. 3rd ed. Paris. Available from: https://gallica.bnf.fr/ark:/12148/bpt6k5810074h/f378.image.langEN; 1869
  7. 7. RedRampant.com: Roman Medicinal Herbs. Available from: http://www.redrampant.com/2009/07/roman-medicinal-herbs.html [Accessed: 8 July 2019]
  8. 8. Al-Snafi AE. The pharmaceutical importance of Althaea officinalis and Althaea rosea: A review. International Journal of PharmTech Research. 2013;5:1378-1385
  9. 9. Ding Z, Dai Y, Hao H, Pan R, Yao X, Wang Z. Anti-inflammatory effects of scopoletin and underlying mechanisms. Pharmaceutical Biology. 2008;46:854-860
  10. 10. Kita T, Fujimura M, Ogawa H, Nakatsumi Y, Nomura S, Ishiura Y, et al. Antitussive effects of the leukotriene receptor antagonist montelukast in patients with cough variant asthma and atopic cough. Allergology International. New York: Springer; 2010;59:185-192
  11. 11. Smith LJ, Kern R, Patterson R, Krell RD, Bernstein PR. Mechanism of leukotriene D4-induced bronchoconstriction in normal subjects. The Journal of Allergy and Clinical Immunology. 1987;80:340-347
  12. 12. Aehringhaus U, Wölbling RH, König W, Patrono C, Peskar BM, Peskar BA. Release of leukotriene C4 from human polymorphonuclear leucocytes as determined by radioimmunoassay. FEBS Letters. 1982;146:111-114
  13. 13. van Tellingen C. Pliny’s pharmacopoeia or the Roman treat. Netherlands Heart Journal. 2007;15:118-120
  14. 14. Naghibi Harat Z, Lakpour N, Sadeghipoor HR, Kamalinejad M, Eshraghian MR, Naghibi B, et al. Immobilising effect of Ruta graveolens L. on human spermatozoa: Coumarin compounds are involved. Andrologia. 2015;47:1183-1189
  15. 15. Strauss U, Wissel K, Jung S, Wulff H, Hänsel W, Zhu J, et al. K(+) channel-blocking alkoxypsoralens inhibit the immune response of encephalitogenic T line cells and lymphocytes from Lewis rats challenged for experimental autoimmune encephalomyelitis. Immunopharmacology. 2000;48:51-63
  16. 16. Schofield FW. The cause of a new disease in cattle stimulating hemorrhagic septicaemia and blackleg. Journal of the American Veterinary Medical Association. 1924;64:553-575
  17. 17. Stahmann MA, Huebner CF, Link KP. Studies on the hemorrhagic sweet clover disease. V. Identification and synthesis of the hemorrhagic agent. The Journal of Biological Chemistry. 1941;138:513-527
  18. 18. Hayes WJ. Control of Norway rats with residual rodenticide warfarin. Public Health Reports. 1950;65:1537-1555
  19. 19. Green P. Haemorrhagic diathesis attributed to warfarin poisoning. Canadian Medical Association Journal. 1955;72:769-770
  20. 20. Wolff JM, Barker NW, Gifford RW, Mann FD. Experience with a new intravenous coumarin anticoagulant (warfarin, sodium derivative). Proceedings of the Staff Meetings. Mayo Clinic. 1953;28:489-497
  21. 21. Shapiro S. Warfarin sodium derivative: (Coumadin® sodium). Angiology. 1953;4:380-390
  22. 22. Ramachandran S, Pitchai S. Story of warfarin: From rat poison to lifesaving drug. Indian Journal of Vascular and Endovascular Surgery. 2018;5:174-175
  23. 23. Minary A, Michel B, Gourieux B, Vogel T. Anticoagulant and antiplatelet combined therapy in patients 75 years and over with atrial fibrillation: A prospective observational study assessing adherence to clinical guidelines. European Journal of Hospital Pharmacy. 2018;0:1-6
  24. 24. Zylla MM, Pohlmeier M, Hess A, Mereles D, Kieser M, Bruckner T, et al. Prevalence of intracardiac thrombi under phenprocoumon, direct oral anticoagulants (dabigatran and rivaroxaban), and bridging therapy in patients with atrial fibrillation and flutter. The American Journal of Cardiology. 2015;115:635-640
  25. 25. Hohmann C, Hohnloser SH, Jacob J, Walker J, Baldus S, Pfister R. Non-vitamin K oral anticoagulants in comparison to phenprocoumon in geriatric and non-geriatric patients with non-valvular atrial fibrillation. Thrombosis and Haemostasis. 2019;119:971-980
  26. 26. Ogletree ML. Overview of physiological and pathophysiological effects of thromboxane A2. Federation Proceedings. 1987;46:133-138
  27. 27. Dahlbäck B. Blood coagulation. Lancet. 2000;355:1627-1632
  28. 28. Boron W, Boulpaep E. Medical Physiology. Philadelphia: Elsevier; 2016
  29. 29. Levy G. Protein binding of warfarin. British Journal of Clinical Pharmacology. 1995;39:211
  30. 30. Breckenridge A, Orme M. Kinetics of warfarin absorption in man. Clinical Pharmacology and Therapeutics. 1973;14:955-961
  31. 31. Stella VJ, Mooney KG, Pipkin JD. Dissolution and ionization of warfarin. Journal of Pharmaceutical Sciences. 1984;73:946-948
  32. 32. Hornton JD, Bushwick BM. Warfarin Therapy: Evolving Strategies in Anticoagulation. USA: American Academy of Family Physicians; 1999. Available from: https://www.aafp.org/afp/1999/0201/p635.html. [Accessed: 9 July 2019]
  33. 33. Kuruvilla M, Gurk-Turner C. A review of warfarin dosing and monitoring. Proceedings (Baylor University. Medical Center). 2001;14:305-306
  34. 34. Kaminsky LS, Zhang ZY. Human P450 metabolism of warfarin. Pharmacology & Therapeutics. 1997;73:67-74
  35. 35. Obaseki AO, Coker HB. The anticoagulant activity of some selected warfarin analogues. The Journal of Pharmacy and Pharmacology. 1987;39:142-144
  36. 36. Chan E, McLachlan AJ, Rowland M. Renal handling of warfarin metabolites in man. European Journal of Pharmaceutical Sciences. 1994;1:189-193
  37. 37. Jähnchen E, Meinertz T, Gilfrich HJ, Kersting F, Groth U. Enhanced elimination of warfarin during treatment with cholestyramine. British Journal of Clinical Pharmacology. 1978;5:437-440
  38. 38. Whitlon DS, Sadowski JA, Suttie JW. Mechanism of coumarin action: Significance of vitamin K epoxide reductase inhibition. Biochemistry. 1978;17:1371-1377
  39. 39. Turpie AGG, Chin BSP, Lip GYH. Venous thromboembolism: Pathophysiology, clinical features, and prevention. BMJ. 2002;325:887-890
  40. 40. Hawes EM, Viera AJ. Anticoagulation: Monitoring of patients receiving anticoagulation. FP Essent. 2014;422:24-30
  41. 41. Ramos-Esquivel A. Monitoring anticoagulant therapy with new oral agents. World Journal of Methodology. 2015;5:212-215
  42. 42. Md Arif K, Rahman MA. A review of warfarin dosing and monitoring. Faridpur Medical College Journal. 2018;13:40-43
  43. 43. Siguret V, Gouin I, Debray M, Perret-Guillaume C, Boddaert J, Mahé I, et al. Initiation of warfarin therapy in elderly medical inpatients: A safe and accurate regimen. The American Journal of Medicine. 2005;118:137-142
  44. 44. Streiff MB, Agnelli G, Connors JM, Crowther M, Eichinger S, Lopes R, et al. Guidance for the treatment of deep vein thrombosis and pulmonary embolism. Journal of Thrombosis and Thrombolysis. 2016;41:32-67
  45. 45. Christensen H, Cordonnier C, Kõrv J, Lal A, Ovesen C, Purrucker JC, et al. European stroke organisation guideline on reversal of oral anticoagulants in acute intracerebral haemorrhage. European Stroke Journal. 2019;0:1-13. DOI: 10.1177/2396987319849763
  46. 46. Li TC, Smith ARB, Duncan SLB. Feto-maternal haemorrhage complicating warfarin therapy during pregnancy. Journal of Obstetrics and Gynaecology. 1990;10:401-402
  47. 47. Soma-Pillay P, Nene Z, Mathivha TM, Macdonald AP. The effect of warfarin dosage on maternal and fetal outcomes in pregnant women with prosthetic heart valves. Obstetric Medicine. 2011;4:24-27
  48. 48. Wainwright H, Beighton P. Warfarin embryopathy: Fetal manifestations. Virchows Archiv. 2010;457:735-739
  49. 49. Sansone RA, Sansone LA. Warfarin and antidepressants: Happiness without hemorrhaging. Psychiatry (Edgmont). 2009;6:24-29
  50. 50. Mehndiratta S, Suneja A, Gupta B, Bhatt S. Fetotoxicity of warfarin anticoagulation. Archives of Gynecology and Obstetrics. 2010;282:335-337
  51. 51. Pauli RM, Lian JB, Mosher DF, Suttie JW. Association of congenital deficiency of multiple vitamin K-dependent coagulation factors and the phenotype of the warfarin embryopathy: Clues to the mechanism of teratogenicity of coumarin derivatives. American Journal of Human Genetics. 1987;41:566
  52. 52. Hou J-W. Fetal warfarin syndrome. Chang Gung Medical Journal. 2004;27:691-695
  53. 53. Vitale N, De Feo M, De Santo LS, Pollice A, Tedesco N, Cotrufo M. Dose-dependent fetal complications of warfarin in pregnant women with mechanical heart valves. Journal of the American College of Cardiology. 1999;33:1637-1641
  54. 54. Menon RK, Gill DS, Thomas M, Kernoff PBA, Dandona P. Impaired carboxylation of osteocalcin in warfarin-treated patients. The Journal of Clinical Endocrinology and Metabolism. 1987;64:59-61
  55. 55. Pati S, Helmbrecht GD. Congenital schizencephaly associated with in utero warfarin exposure. Reproductive Toxicology. 1994;8:115-120
  56. 56. Schindler D, Graham TP. Warfarin overdose in a breast-feeding woman. The Western Journal of Emergency Medicine. 2011;12:216-217
  57. 57. Yurdakök M. Fetal and neonatal effects of anticoagulants used in pregnancy: A review. The Turkish Journal of Pediatrics. 2012;54:207-215
  58. 58. Ní Áinle F, Wong A, Appleby N, Byrne B, Regan C, Hassan T, et al. Efficacy and safety of once daily low molecular weight heparin (tinzaparin sodium) in high risk pregnancy. Blood Coagulation and Fibrinolysis. 2008;19(7):689-692
  59. 59. Pirmohamed M, James S, Meakin S, Green C, Scott AK, Walley TJ, et al. Adverse drug reactions as cause of admission to hospital: Prospective analysis of 18 820 patients. BMJ. 2004;329:15-19
  60. 60. Linkins L-A, Choi PT, Douketis JD. Clinical impact of bleeding in patients taking oral anticoagulant therapy for venous thromboembolism. Annals of Internal Medicine. 2003;139:893
  61. 61. Wallvik J, Själander A, Johansson L, Bjuhr O, Jansson J-H. Bleeding complications during warfarin treatment in primary healthcare centres compared with anticoagulation clinics. Scandinavian Journal of Primary Health Care. 2007;25:123-128
  62. 62. Zareh M, Davis A, Henderson S. Reversal of warfarin-induced hemorrhage in the emergency department. The Western Journal of Emergency Medicine. 2011;12:386-392
  63. 63. Fitzmaurice DA, Blann AD, Lip GYH. Bleeding risks of antithrombotic therapy. BMJ. 2002;325:828-831
  64. 64. Mogyorosi A, Bradley B, Showalter A, Schubert ML. Rhabdomyolysis and acute renal failure due to combination therapy with simvastatin and warfarin. Journal of Internal Medicine. 1999;246:599-602
  65. 65. Mendonca S, Gupta D, Valsan A, Tewari R. Warfarin related acute kidney injury: A case report. Indian Journal of Nephrology. 2017;27:78-80
  66. 66. Kapoor KG, Bekaii-Saab T. Warfarin-induced allergic interstitial nephritis and leucocytoclastic vasculitis. Internal Medicine Journal. 2008;38:281-283
  67. 67. Kwong P, Roberts P, Prescott SM, Tikoff G. Dermatitis induced by warfarin. JAMA. 1978;239:1884-1885
  68. 68. Sarin S, Mukhtar H, Mirza MA. Prolonged coagulopathy related to superwarfarin overdose. Annals of Internal Medicine. 2005;142:156
  69. 69. Watt BE, Proudfoot AT, Bradberry SM, Vale JA. Anticoagulant rodenticides. Toxicological Reviews. 2005;24:259-269
  70. 70. Blickstein D, Shaklai M, Inbal A. Warfarin antagonism by avocado. Lancet. 1991;337:914-915
  71. 71. Zhou C, Sui Y, Zhao W, Dong C, Ren L, Song P, et al. The critical interaction between valproate sodium and warfarin: Case report and review. BMC Pharmacology and Toxicology. 2018;19:60
  72. 72. Carpenter M, Berry H, Pelletier AL. Clinically relevant drug-drug interactions in primary care. American Family Physician. 2019;99:558-564
  73. 73. Hayes A, Hennessy Á, Walton J, McNulty BA, Lucey AJ, Kiely M, et al. Phylloquinone intakes and food sources and vitamin K status in a nationally representative sample of Irish adults. The Journal of Nutrition. 2016;146:2274-2280
  74. 74. Booth SL. Vitamin K: Food composition and dietary intakes. Food & Nutrition Research. 2012;56:1-5. DOI: 10.3402/fnr.v56i0.5505
  75. 75. Conly JM, Stein K. The production of menaquinones (vitamin K2) by intestinal bacteria and their role in maintaining coagulation homeostasis. Progress in Food & Nutrition Science. 1992;16:307-343
  76. 76. Li J, Wang S, Barone J, Malone B. Warfarin pharmacogenomics. P T. 2009;34:422-427
  77. 77. Mak M, Lam C, Pineda SJ, Lou M, Xu LY, Meeks C, et al. Pharmacogenetics of warfarin in a diverse patient population. Journal of Cardiovascular Pharmacology and Therapeutics. 2019;24:521-533. DOI: 10.1177/1074248419843530
  78. 78. Sanoski CA, Bauman JL. Clinical observations with the amiodarone/warfarin interaction: Dosing relationships with long-term therapy. Chest. 2002;121:19-23
  79. 79. Linville D II, Emory C, Graves L III. Ciprofloxacin and warfarin interaction. The American Journal of Medicine. 1991;90:765
  80. 80. Hemeryck A, De Vriendt C, Belpaire FM. Inhibition of CYP2C9 by selective serotonin reuptake inhibitors: In vitro studies with tolbutamide and (S)-warfarin using human liver microsomes. European Journal of Clinical Pharmacology. 1999;54:947-951
  81. 81. Nutescu E, Chuatrisorn I, Hellenbart E. Drug and dietary interactions of warfarin and novel oral anticoagulants: An update. Journal of Thrombosis and Thrombolysis. 2011;31:326-343
  82. 82. Choi KH, Kim AJ, Son IJ, Kim K-H, Kim K-B, Ahn H, et al. Risk factors of drug interaction between warfarin and nonsteroidal anti-inflammatory drugs in practical setting. Journal of Korean Medical Science. 2010;25:337-341
  83. 83. Thijssen HH, Soute BA, Vervoort LM, Claessens JG. Paracetamol (acetaminophen) warfarin interaction: NAPQI, the toxic metabolite of paracetamol, is an inhibitor of enzymes in the vitamin K cycle. Thrombosis and Haemostasis. 2004;92:797-802
  84. 84. Buckley MS, Goff AD, Knapp WE. Fish oil interaction with warfarin. The Annals of Pharmacotherapy. 2004;38:50-53
  85. 85. Jarvis S, Li C, Bogle RG. Possible interaction between pomegranate juice and warfarin. Emergency Medicine Journal. 2010;27:74-75
  86. 86. Knudsen JF, Sokol GH. Potential glucosamine-warfarin interaction resulting in increased international normalized ratio: Case report and review of the literature and MedWatch database. Pharmacotherapy. 2008;28:540-548
  87. 87. Segal R, Pilote L. Warfarin interaction with Matricaria chamomilla. CMAJ. 2006;174:1281-1282
  88. 88. Janetzky K, Morreale AP. Probable interaction between warfarin and ginseng. American Journal of Health-system Pharmacy. 1997;54:692-693
  89. 89. Henderson L, Yue QY, Bergquist C, Gerden B, Arlett P. St John’s wort (Hypericum perforatum): Drug interactions and clinical outcomes. British Journal of Clinical Pharmacology. 2002;54:349-356
  90. 90. Little JW. New oral anticoagulants: Will they replace warfarin? Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology. 2012;113:575-580
  91. 91. Collins AK, Makrigiorgos GM, Svensson GK. Coumarin chemical dosimeter for radiation therapy. Medical Physics. 1994;21:1741-1747
  92. 92. Maresca A, Temperini C, Pochet L, Masereel B,Scozzafava A, Supuran CT. Deciphering the mechanism of carbonic anhydrase inhibition with coumarins and thiocoumarins. Journal of Medicinal Chemistry. 2010;53:335-344
  93. 93. Carta F, Supuran CT. Diuretics with carbonic anhydrase inhibitory action: A patent and literature review (2005-2013). Expert Opinion on Therapeutic Patents. 2013;23:681-691
  94. 94. Lee S, Shin D-S, Ju SK, Oh K-B, Sam SK. Antibacterial coumarins from Angelica gigas roots. Archives of Pharmacal Research. 2003;26:449-452
  95. 95. Cuzzocrea S, Mazzon E, Bevilaqua C, Costantino G, Britti D, Mazzullo G, et al. Cloricromene, a coumarine derivative, protects against collagen-induced arthritis in Lewis rats. British Journal of Pharmacology. 2000;131:1399-1407
  96. 96. Klenkar J, Molnar M. Natural and synthetic coumarins as potential anticancer agents. Journal of Chemical and Pharmaceutical Research. 2015;7:1223-1238

Written By

Robbert Bipat

Submitted: July 11th, 2019 Reviewed: September 17th, 2019 Published: October 17th, 2019